Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
Xilio Therapeutics, Inc. (XLO)
Company Research
Source: GlobeNewswire
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company’s board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026. “Cheryl brings over three decades of leadership experience advancing the development of innovative products across biologics, small molecules and medical devices, and I am pleased to welcome her to the board,” said Sara Bonstein, chair of the board of directors of Xilio. “We look forward to leveraging her expertise as we advance our next generation of innovative, multi-specific I-O therapies toward the clinic. On behalf of the entire board, I would also like to thank Christy for her invaluable contributions to Xilio over the past five years.” Dr. Bl
Show less
Read more
Impact Snapshot
Event Time:
XLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XLO alerts
High impacting Xilio Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
XLO
News
- Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 [Yahoo! Finance]Yahoo! Finance
- Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2GlobeNewswire
- Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Xilio Therapeutics (XLO) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=XLO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" tMarketBeat
- Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
XLO
Sec Filings
- 4/28/26 - Form ARS
- 4/28/26 - Form DEF
- 4/16/26 - Form 4
- XLO's page on the SEC website